For help on how to get the results you want, see our search tips.
2 results
Medicine type
Conditional approval Remove Conditional approval filter
Additional monitoring Remove Additional monitoring filter
Medicine
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Referrals Remove Referrals filter
Referral safety status
Yes Remove Yes filter
Referral type
Article 31 referrals Remove Article 31 referrals filter
Article 20 procedures Remove Article 20 procedures filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Categories
Human Remove Human filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020